c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer.

[1]  A. Andersson,et al.  S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. , 1994, British Journal of Cancer.

[2]  M. Fernö,et al.  ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. , 1994, Cancer letters.

[3]  S. Wingren,et al.  Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. , 1994, Cytometry.

[4]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[5]  S Toikkanen,et al.  Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Gera,et al.  Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis. , 1992, Cellular immunology.

[8]  P. V. van Diest,et al.  Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression. Preliminary results. , 1992, Pathology, research and practice.

[9]  C. Osborne,et al.  HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D M Barnes,et al.  Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? , 1992, European journal of cancer.

[11]  A. Auquier,et al.  Post-mastectomy megavoltage radiotherapy: the Oslo and Stockholm trials. , 1992, European journal of cancer.

[12]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[13]  T. Visakorpi,et al.  Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.

[14]  S. Ménard,et al.  Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.

[15]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[16]  B. Angus,et al.  Long‐term survival in breast cancer related to overexpression of the c‐erbB‐2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL‐CB11 , 1991, The Journal of pathology.

[17]  H. Kooy,et al.  Early breast cancer: predictors of breast recurrence for patients treated with conservative surgery and radiation therapy. , 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  D. Weiner,et al.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation , 1989, Nature.

[19]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[20]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[21]  L. Skoog,et al.  Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials. , 1989, International journal of radiation oncology, biology, physics.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  N. Lemoine,et al.  c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study. , 1994, European journal of cancer.

[24]  G. Wishart,et al.  Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 , 1993 .

[25]  S. Paik.  Clinical significance of erbB-2 (HER-2/neu) protein. , 1992, Cancer investigation.

[26]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992, Lancet.

[27]  D. Cox.  Regression Models and Life-Tables , 1972 .